The developer of a lifesaving new platform that can detect early signs of bacterial sepsis has been revealed as the first company to secure funding from the Liverpool City Region’s innovation fund.
Frequasense Ltd has secured £175,000 from LYVA Labs to develop technology that quickly detects sepsis
Once fully developed, Frequasense’s platform, which involves a rapid finger prick test, will be used by hospitals, GP practices, nursing homes and paramedics.
Sonja Jonas, CEO of Frequasense, said, “We have worked tirelessly to develop our platform, which will save the lives of so many people who will be diagnosed with sepsis. This investment from LYVA Labs will provide us with the funding and support we need to accelerate our offering to its final development stage.
“We have established a fantastic relationship with the LYVA Labs team and look forward to relocating to the city area and receiving the support we need to secure the future of this vital platform.”
LYVA Labs was established with a £10.5m investment from the Liverpool City Region Combined Authority announced by Mayor Steve Rotheram in August 2021. Frequasense’s product is the first investment made by the scheme since the successful launch from the LCR Ventures Challenge Fund earlier this year.
The investment will enable Frequasense to secure an Innovate UK SMART grant of £300,000 to complete the development and testing of its product in a clinical setting. It will be supported by the Liverpool University Hospital Foundation Trust (LUHFT) and the Liverpool School of Tropical Medicine.